Rohto Pharmaceutical announced its earnings. First-quarter ordinary profit fell to ¥14.4 billion, while its full-year ordinary profit forecast was raised by 2.8% to ¥47.4 billion. The operating margin on net sales for the past 3 months improved to 14.9%.
Rohto Pharmaceutical announced its earnings after the market close on 6 August. Consolidated ordinary profit for the first quarter of the fiscal year ending March 2027 (April-June) was approximately ¥14.4 billion, down 10.1% year on year.
At the same time, the company raised its full-year ordinary profit forecast from the previous estimate of ¥46.1 billion to ¥47.4 billion. Ordinary profit was ¥47.9 billion in the previous fiscal year. The revision represents an increase of 2.8%, and the decline in profit is now expected to narrow.
The operating margin on net sales for the past 3 months rose to 14.9% from 14.3% in the same period of the previous year. The company released its earnings summary PDF, and attention is now focused on the subsequent trend in its performance.